Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways
Abstract Background Mesothelioma is resistant to conventional treatments and is often defective in p53 pathways. We then examined anti-tumor effects of metformin, an agent for type 2 diabetes, and combinatory effects of metformin and nutlin-3a, an inhibitor for ubiquitin-mediated p53 degradation, on...
Main Authors: | Kengo Shimazu, Yuji Tada, Takao Morinaga, Masato Shingyoji, Ikuo Sekine, Hideaki Shimada, Kenzo Hiroshima, Takao Namiki, Koichiro Tatsumi, Masatoshi Tagawa |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-05-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-017-3300-y |
Similar Items
-
Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells
by: Veronica Tisato, et al.
Published: (2014-01-01) -
Nutlin3a Contributes to the Cytoplasmic Retention of Androgen Receptor
by: Gulseren Ozduman, et al.
Published: (2018-12-01) -
Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells
by: Yiyang Qin, et al.
Published: (2017-12-01) -
Dynamic behavior of the p53-Mdm2 core module under the action of drug Nutlin and dual delays
by: Juenu Yang, et al.
Published: (2021-05-01) -
A Potential Therapeutic Strategy for Malignant Mesothelioma with Gene Medicine
by: Yuji Tada, et al.
Published: (2013-01-01)